JPRN-jRCT2052190025进行中（未招募）3 期
Multi-center, open-label, single-arm study on the endovascular visualization capability of an OFDI (Optical Frequency Domain Imaging) catheter for obstructive arteriosclerosis of lower extremities
Hirata Ken-ichi0 个研究点目标入组 20 人开始时间: 2019年6月3日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Patients who undergo endovascular treatment based on guidelines for the management of PAD (peripheral arterial diseases) (JCS 2015) (2) Patients whose target lesion site exists from the superficial femoral artery to the peripheral side (3) Patients who are at least 20 years at the time of consent acquisition
排除标准
- •(1) Patients who have a history of bypass surgery (2) Patients with endovascular treatment (stent placement excluding balloon treatment) for PAD of lower extremities in the past and re-treat the same lesion (3) Patients who have serious allergies to contrast (4) Patients who have renal dysfunction with eGFR (MDRD calculation formula) less than 30 mL / min / 1.73 m2 (5) Patients with platelet count less than 100000 / microL (6) Patients contraindicated for antiplatelet or anticoagulant therapy (7)Patients decided not applicable for this study by physician
研究者
相似试验
进行中（未招募）
1 期
An open-label study for the safety and efficacy of pomalidomide in refractory or refractory/relapsed multiple myeloma subjectsEUCTR2010-023343-16-GBCelgene Corporation74
进行中（未招募）
不适用
An open-label study for the safety and efficacy of pomalidomide in refractory or refractory/relapsed multiple myeloma subjectsEUCTR2010-023343-16-BECelgene Corporation85
进行中（未招募）
不适用
An open-label study for the safety and efficacy of pomalidomide in refractory or refractory/relapsed multiple myeloma subjectsRefractory or relapsed and refractory multiple myelomaMedDRA version: 16.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2010-023343-16-DECelgene Corporation85
进行中（未招募）
不适用
An open-label study for the safety and efficacy of pomalidomide in refractory or refractory/relapsed multiple myeloma subjectsEUCTR2010-023343-16-NLCelgene Corporation70
进行中（未招募）
不适用
An open-label study for the safety and efficacy of pomalidomide inrefractory or refractory/relapsed multiple myeloma subjectsRefractory or relapsed and refractory multiple myelomaMedDRA version: 13.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023343-16-GRCelgene Corporation85